Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Jupiter enters psychedelics space with $100M deal for PharmAla’s MDMA drug

Jupiter enters psychedelics space with $100M deal for PharmAla’s MDMA drug

July 21, 2026Posted inBiotechnology

Jupiter Neurosciences will pay $3.3 million upfront to Canada’s PharmAla Biotech for U.S. rights to an MDMA drug to treat neuropsychiatric disorders.

Post navigation

Previous Post
Agios says adios to sickle cell program over lackluster phase 2 data
Next Post
Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later revvity-creates-program-to-equip-young-biotechs-with-scalable-informatics-capabilities-sooner-than-later

Recent Posts

  • Why Novartis CEO ended his ADC holdout for $1.5B Myricx deal
  • Revvity Creates Program to Equip Young Biotechs with Scalable Informatics Capabilities Sooner than Later
  • Jupiter enters psychedelics space with $100M deal for PharmAla’s MDMA drug
  • Agios says adios to sickle cell program over lackluster phase 2 data
  • Novartis drops phase 2 radioligand therapy, but CEO’s commitment to modality ‘unchanged’

Archives

  • July 2026
  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • October 2024
  • September 2024
  • August 2024
  • March 2024
  • January 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top